Aberrant signaling pathways in medulloblastomas: a stem cell connection

Arquivos de Neuro-Psiquiatria

Carolina Oliveira Rodini²  Daniela Emi Suzuki¹  Adriana Miti Nakahata²  Márcia Cristina Leite Pereira¹  Luciana Janjoppi¹  Silvia Regina Caminada Toledo¹  Oswaldo Keith Okamoto² 

[1] ,Universidade Federal de São Paulo Laboratory of Experimental Neurology Department of Neurology and NeurosurgerySão Paulo SP ,Brazil

关键词: medulloblastoma;    neurobiology;    signal transduction;    stem cells;    transforming growth factor beta;    biological therapy;    meduloblastoma;    neurobiologia;    transdução de sinal;    células-tronco;    fator transformador de crescimento beta;    terapia biológica;   

DOI  :  10.1590/S0004-282X2010000600021

来源: SciELO

【 摘 要 】

Medulloblastoma is a highly malignant primary tumor of the central nervous system. It represents the most frequent type of solid tumor and the leading cause of death related to cancer in early childhood. Current treatment includes surgery, chemotherapy and radiotherapy which may lead to severe cognitive impairment and secondary brain tumors. New perspectives for therapeutic development have emerged with the identification of stem-like cells displaying high tumorigenic potential and increased radio- and chemo-resistance in gliomas. Under the cancer stem cell hypothesis, transformation of neural stem cells and/or granular neuron progenitors of the cerebellum are though to be involved in medulloblastoma development. Dissecting the genetic and molecular alterations associated with this process should significantly impact both basic and applied cancer research. Based on cumulative evidences in the fields of genetics and molecular biology of medulloblastomas, we discuss the possible involvement of developmental signaling pathways as critical biochemical switches determining normal neurogenesis or tumorigenesis. From the clinical viewpoint, modulation of signaling pathways such as TGFβ, regulating neural stem cell proliferation and tumor development, might be attempted as an alternative strategy for future drug development aiming at more efficient therapies and improved clinical outcome of patients with pediatric brain cancers.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License